Genesis Drug Discovery & Development (GD3)

?? We are thrilled to announce our latest publication “Evaluate the safety of a novel photohydrolysis technology used to clean and disinfect indoor air: A murine study” in PLoS One. ?? Read the full article here: https://lnkd.in/ei-t7svJ ?? We’d love to hear your thoughts!

Are you attending BIOTECH SUMMIT AUSTRIA October 10 – 11 in Innsbruck, Austria? Do you have a small molecule drug candidate or need synthetic organic chemistry or medicinal chemistry services? ?? Connect with Virág at #BSA24 and learn more about how we can provide innovative end-to-end support for your drug discovery & development needs. Virág Bogdándi, Ph.D., Business Development Manager Tel: (+36) 30 6449913 Email: [email protected]

GD3 is excited to announce that we will be a part of the 2024 NIH Fall Research Festival in Bethesda, Maryland. ?? Visit us on Tuesday, September 24th ?? NIH Main Bethesda, Campus Building 10 ?? Connect with one of GD3's experts to learn more about how we can provide innovative support to advance the success of your program. https://lnkd.in/eRPXDeQz

GD3 is excited to announce that we will be a part of the 2024 NIH Fall Research Festival in Bethesda, Maryland. ?? Visit us on Tuesday, September 24th ?? NIH Main Bethesda, Campus Building 10 ?? Connect with one of GD3's experts to learn more about how we can provide innovative support to advance the success of your program. https://lnkd.in/eRPXDeQz

Immunoassays are essential tools in preclinical drug discovery and disease diagnostics. These sophisticated biochemical tests detect small molecules, proteins, nucleic acids, toxins, and other biological substances in a sample by utilizing antibodies that specifically bind to a target analyte or antigen. The resulting antibody-antigen complexes are then quantified by measuring the signal emitted from a detection label. Immunoassays have a wide range of applications, including quantifying test articles, diagnosing infectious diseases, evaluating immune responses to therapeutic candidates, and accurately measuring biomarkers and metabolites for drug development. At GD3, we offer both off-the-shelf and custom immunoassays tailored to meet your unique research requirements. Our scientists deliver quick turnaround times, assays with exceptional sensitivity and reproducibility, and a commitment to delivering high-quality results to advance your programs. Our wide range of services include: ?? ELISAs and ECL-based immunoassays ? Meso Scale Discovery (MSD) immunoassays ? Fluorescence resonance energy transfer (FRET) immunoassays ? Antibody purification and labeling ? I mmunogenicity assays ? Nuclease protection assays ? Ligand binding assays ? And More! Contact us to learn more about how GD3 can help you progress your research. Contact our experts today! https://lnkd.in/eRPXDeQz

August is Psoriasis Action Month. This chronic autoimmune condition affects over 8 million people in the United States. This month, we will raise awareness to drive research for better treatment options. GD3 offers a comprehensive suite of optimized and validated immune-mediated models for assessing allergic and immune-mediated diseases. Our team also excels at developing tailored models to meet specific research needs. Skin models include: ? Delayed type dermal hypersensitivity in mice, rats, rabbits ? Oxazalone, TNBF, DNBF, LPS, Horseshoe crab limulus lysate, BCG ? Atopic Dermatitis ? Imiquimod-induced murine model of psoriasis ? Guinea pig dermal sensitization ? Dermal sensitization ? Beuhler test ? Guinea pig maximization test - Magnusson and Kligman Assay A diverse range of In vivo assessments are available and may include clinical signs, neurologic signs, biomarkers, cytokines, body weights, food consumption, lameness scoring, joint diameter measurement scoring, plesthysmometry, clinical pathology, funduscopy, OCT, laser doppler, sillouette photography and customized assays. ???? Supporting capabilities include hereditary genetic screening, pharmacogenomics testing, gene expression profiling, analysis of protein biomarkers, custom in vitro assay development, preclinical PK/PD, small and large molecule bioanalysis. ?? Extensive worldwide clinical trial experience ? >1,300 clinical trials overall ?? Extensive global network of sites with available performance metrics, academic & community-based ?? Your “One-Stop Shop” ? Study design ? Regulatory ? Project management ? Data management ? Clinical monitoring ? Medical monitoring ? Safety review / pharmacovigilance ? Biostatistical expertise ? Medical writing ?? DISC Gold Member: SDTM/ADaM expertise ?? Connect with one of GD3's experts to learn more about how we can provide innovative support to advance the success of your program. https://lnkd.in/eRPXDeQz

Did you know 1 in 50 people is a genetic carrier for Spinal Muscular Atrophy (SMA)? SMA, the leading genetic cause of infant death, is caused by defects in the Survival Motor Neuron 1 (SMN1) gene that encodes the SMN protein. SMA patients have at least one copy of a similar gene (SMN2) that produces SMN protein, although in reduced amounts. Infantile-onset spinal muscular atrophy is the most common genetic cause of infant mortality, typically resulting in death preceding age two. Low-level production of survival motor neuron protein (SMN) results in a loss of specialized nerve cells called motor neurons that control muscle movement. GD3 researchers have worked with organizations such as the Spinal Muscular Atrophy Foundation, universities and pharmaceutical companies on critical SMA research. In recent years, new SMN-enhancing therapeutics have been developed. Since limited knowledge of baseline and drug-induced SMN levels in disease-relevant tissues hinders efforts to optimize these treatments, clinical trials in this population require understanding disease progression and identifying meaningful biomarkers to hasten therapeutic development and predict outcomes. Clinical studies require a readily accessible means of tracking SMN levels in the patient. GD3 scientists have developed an immunoassay system that monitors SMN protein levels in whole blood. The assay can detect and quantify SMN protein from as little as 5 microliters of whole blood, which can be obtained from a finger prick. ???? Supporting capabilities include gene expression profiling, analysis of protein biomarkers, custom in vitro assay development, preclinical PK/PD, small and large molecule bioanalysis. ?? Extensive worldwide clinical trial experience ? >1,300 clinical trials overall ?? Extensive global network of sites with available performance metrics, academic & community-based ?? Your “One-Stop Shop” ? Study design ? Regulatory ? Project management ? Data management ? Clinical monitoring ? Medical monitoring ? Safety review / pharmacovigilance ? Biostatistical expertise ? Medical writing ?? DISC Gold Member: SDTM/ADaM expertise ?? Connect with one of GD3's experts to learn more about how we can provide innovative support to advance the success of your program. https://lnkd.in/eRPXDeQz

Do you have an ocular therapeutic candidate for which you need safety assessment and toxicology data? The scientists at GD3 have extensive experience collecting and interpreting routine ocular readouts following test article administration through a variety of dose routes, including topical, intravitreal, subretinal and suprachoroidal. Using our state-of-the-art Heidelberg Spectralis HRA + OCT device, we can generate high-quality and consistent optical coherence tomography (OCT), fluorescein angiography (FA) and confocal scanning laser ophthalmoscopy (cSLO) data needed to continue advancing your therapeutic candidate through the drug development pipeline. The experts at GD3 are able to take these readouts a step further by quantitatively assessing visual function through the collection of electroretinograms (ERG) using our Celeris Diagnosys system, which enables our experts to execute the standard International Society for Clinical Electrophysiology of Vision (ISCEV) protocol that is routinely used in clinical studies. At GD3, we are invested in understanding the characteristics of your therapeutic candidate. We can offer guidance and expertise on standard OCT and ERG parameters required to assess ocular safety and toxicology, which can be modified to satisfy client and therapeutic candidate needs. Additional ocular safety assessment and toxicology readouts that are routinely performed and offered at GD3 include: ???? We offer additional ocular safety assessment and toxicology readouts that are routinely performed and offered at GD3 including: ? Indirect and slit lamp ocular examinations performed by a board-certified veterinary ophthalmologist ? Intraocular Pressure ? Pachymetry ? Modified Draize Scoring ? Depot imaging ? Data interpretation and summary of ocular readouts performed by a board-certified veterinary ophthalmologist ? Histopathological assessment with a board-certified pathologist ? Biomarker evaluation ? Gene expression analysis ? Bioanalysis for small molecules, peptides, proteins and nucleic-acid-based therapeutics ?? Connect with one of GD3's experts to learn more about how we can provide innovative support to advance the success of your program. https://lnkd.in/eRPXDeQz

August 18th marks World Breast Cancer Research Day, a poignant reminder of the one in eight women who will face this devastating diagnosis. This day honors the relentless dedication of researchers striving for groundbreaking treatments and a future free from this disease. ?? With a deep-rooted focus on oncology, GD3’s scientists excel in a wide range of studies, including xenografts, pharmacology, toxicology, and histopathology. Our comprehensive capabilities extend to small molecules, biologics, immunotherapy, gene therapy, stem cell research, and medical device development. ???? Supporting capabilities include clinical pathology, immunology, histopathology, immunohistochemistry, hereditary genetic screening, pharmacogenomics testing, analysis of inflammatory cytokines, gene expression profiling, analysis of protein biomarkers, custom in vitro assay development, preclinical PK/PD, small and large molecule bioanalysis. ?? Extensive worldwide clinical trial experience ? >1,300 clinical trials overall ?? Extensive global network of sites with available performance metrics, academic & community-based ?? Your “One-Stop Shop” ? Study design ? Regulatory ? Project management ? Data management ? Clinical monitoring ? Medical monitoring ? Safety review / pharmacovigilance ? Biostatistical expertise ? Medical writing ?? DISC Gold Member: SDTM/ADaM expertise ?? Connect with one of GD3's experts to learn more about how we can provide innovative support to advance the success of your program. https://lnkd.in/eRPXDeQz

The first synthesis of acetylsalicylic acid was performed on the 10th of August 1897 by the German chemist Felix Hoffmann, who found that the addition of an acetyl group to salicylic acid reduced its irritant properties like nausea, tinnitus or gastric irritation. However, the appealing history of acetylsalicylic acid dates back to ancient times, when meadow sweet, willow and myrtle were used to relieve pain. Aspirin, the brand name of acetylsalicylic acid given by the German company Bayer, recognizes the fascinating herbal medicine from the past as "Spir" comes from the plant "Spiraea ulmaria" or meadow sweet, attributed as the botanical source of salicylic acid. Although the development of paracetamol and ibuprofen reduced the popularity of Aspirin, it is still the most commonly used drug in the world, is on the World Health Organization's List of Essential Medicines and has entered the Guinness Book of Records as the highest-selling painkiller. Speak with one of GD3's experts to learn more about our deep experience in medicinal chemistry and how we can advance your drug discovery and development program. Click here to reach a member of our team! https://lnkd.in/eRPXDeQz